Thoracic Neoplasms: Clinical Trials

4795 completed, 1965 unknown, 1912 recruiting, 1350 terminated. 4465 Phase 2, 2734 Phase 1, 2019 Not applicable, 1129 Phase 3, 169 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	4465	Completed 1704, Unknown 716, Recruiting 663, Terminated 609, Active not recruiting 319, Not yet recruiting 241, Withdrawn 191, Suspended 14, Enrolling by invitation 8
Phase 1	2734	Completed 1098, Terminated 497, Recruiting 469, Active not recruiting 239, Unknown 234, Withdrawn 100, Not yet recruiting 77, Suspended 17, Enrolling by invitation 3
Not applicable	2019	Completed 795, Recruiting 367, Unknown 359, Not yet recruiting 154, Terminated 144, Active not recruiting 120, Withdrawn 66, Enrolling by invitation 11, Suspended 3
Phase 3	1129	Completed 445, Recruiting 170, Unknown 165, Terminated 138, Active not recruiting 134, Not yet recruiting 49, Withdrawn 23, Enrolling by invitation 3, Suspended 2
Phase 4	169	Completed 76, Unknown 34, Recruiting 20, Terminated 18, Not yet recruiting 10, Active not recruiting 4, Withdrawn 4, Suspended 3
Early Phase 1	119	Completed 30, Unknown 25, Terminated 19, Recruiting 16, Not yet recruiting 12, Withdrawn 8, Active not recruiting 4, Enrolling by invitation 3, Suspended 2

Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer	Not applicable	Not yet recruiting	FranciscoVeraSerrano	84	2028-01-01	2026-03-17
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	RemeGen Co., Ltd.	26	2027-12-01	2026-09-22
Symptom Management to Improve Completion of Patient-reported Outcome Measures Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm	Not applicable	Not yet recruiting	Henry Ford Health System	78	2027-10-01	2026-07-29
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods Real-Time Image Guided Radio Therapy (IGRT) - Cancer	Not applicable	Not yet recruiting	University of Sydney	40	2027-06-01	2026-05-20
Antigen-specific T Cells Against Lung Cancer Lung cancer-specific T cells - Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2027-06-01	2026-08-26
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer	Phase 1	Suspended	UNC Lineberger Comprehensive Cancer Center	6	2027-05-20	2026-04-23
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records Lung Cancer		Not yet recruiting	AstraZeneca	3000	2027-04-01	2026-06-02
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer	Phase 1	Not yet recruiting	M.D. Anderson Cancer Center	24	2027-04-01	2026-10-28
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	336	2027-03-02	2026-10-28
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung	Phase 1 / Phase 2	Not yet recruiting	Xemed LLC	10	2027-03-01	2026-09-01
Virtual Reality in Lung Cancer Patients Immersive Virtual Reality - Lung Neoplasms (D008175)	Not applicable	Not yet recruiting	Dott.Claudio Sini	60	2027-03-01	2026-08-12
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors Artificial Intelligence-based Intervention, Best Practice, Computed Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma	Not applicable	Not yet recruiting	Northwestern University	34	2027-02-13	2026-10-27
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas Sacituzumab Tirumotecan (Sac-TMT) - Unresectable Thymic Carcinoma	Phase 2	Not yet recruiting	National Cancer Center, Japan	35	2027-02-01	2026-08-06
DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer	Phase 1	Recruiting	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	6	2027-01-31	2026-09-29
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer	Phase 1	Suspended	University of Maryland, Baltimore	50	2027-01-30	2026-09-14
Witness Project Lung Witness Project Lung, General Educational Program - Lung Cancer	Not applicable	Not yet recruiting	Hackensack Meridian Health	400	2027-01-15	2026-08-28
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1 / Phase 2	Not yet recruiting	Nob Hill Therapeutics, Inc.	100	2027-01-11	2026-10-08
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer	Phase 3	Not yet recruiting	AbbVie	660	2027-01-06	2026-10-05
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise	Not applicable	Not yet recruiting	Izmir Bakircay University	78	2027-01-04	2026-10-21
Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization Multiparametric chest MRI with diffusion-weighted imaging - Solitary Pulmonary Nodule, Multiple Pulmonary Nodules		Not yet recruiting	University of Florida	30	2027-01-01	2026-08-19

Showing 20 of 12048. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (7074)  ·  Lung Neoplasms (5261)  ·  Small Cell Lung Carcinoma (1200)  ·  Breast Neoplasms (888)  ·  Neoplasms (778)  ·  Colorectal Neoplasms (693)  ·  Melanoma (574)  ·  Ovarian Neoplasms (514)  ·  Pancreatic Neoplasms (496)  ·  Neoplasm Metastasis (489)  ·  Stomach Neoplasms (410)  ·  Adenocarcinoma of Lung (404)  ·  Head and Neck Neoplasms (385)  ·  Prostatic Neoplasms (376)  ·  Carcinoma, Renal Cell (353)

Broader conditions

Neoplasms by Site (11996)  ·  Respiratory Tract Neoplasms (11819)  ·  Respiratory Tract Diseases (11712)  ·  Lung Diseases (11488)  ·  Neoplasms (11270)  ·  Bronchial Neoplasms (7908)  ·  Carcinoma, Bronchogenic (7889)  ·  Lung Neoplasms (6496)  ·  Neoplasms by Histologic Type (2445)  ·  Neoplasms, Glandular and Epithelial (1959)  ·  Digestive System Diseases (1527)  ·  Digestive System Neoplasms (1489)  ·  Skin and Connective Tissue Diseases (1428)  ·  Skin Diseases (1418)

Interventions

Carboplatin (1083)  ·  Cisplatin (820)  ·  Pemetrexed (761)  ·  pembrolizumab (589)  ·  Paclitaxel (580)  ·  Docetaxel (500)  ·  Gemcitabine (395)  ·  Radiotherapy (373)  ·  Erlotinib Hydrochloride (339)  ·  Nivolumab (323)  ·  Bevacizumab (294)  ·  Etoposide (268)  ·  durvalumab (237)  ·  Drug Therapy (226)  ·  osimertinib (210)

Sponsors

National Cancer Institute (NCI) (319)  ·  AstraZeneca (233)  ·  M.D. Anderson Cancer Center (199)  ·  Memorial Sloan Kettering Cancer Center (164)  ·  Eli Lilly and Company (160)  ·  Pfizer (139)  ·  Sun Yat-sen University (129)  ·  Bristol-Myers Squibb (111)  ·  Novartis Pharmaceuticals (110)  ·  Hoffmann-La Roche (106)  ·  Alliance for Clinical Trials in Oncology (97)  ·  Merck Sharp & Dohme LLC (94)  ·  Shanghai Chest Hospital (94)  ·  Shanghai Pulmonary Hospital, Shanghai, China (90)  ·  Fudan University (82)

Countries

United States (5066)  ·  China (2716)  ·  France (1165)  ·  Spain (1012)  ·  Italy (944)  ·  Canada (920)  ·  South Korea (862)  ·  United Kingdom (797)  ·  Germany (765)  ·  Taiwan (628)  ·  Australia (599)  ·  Netherlands (566)  ·  Belgium (540)  ·  Japan (519)  ·  Poland (478)

Top investigators

Mariano Provencio, MD (21)

Results publications

PMID 27130468, PMID 33538338, PMID 34393061, PMID 37419867, PMID 40311309, PMID 21714641, PMID 22586319, PMID 23442309, PMID 26291008, PMID 26291023, PMID 27718847, PMID 30207593, PMID 34870327, PMID 37465924, PMID 39113428, PMID 39462179, PMID 42820295, PMID 19692680, PMID 25175099, PMID 25881079, PMID 26104945, PMID 27959700, PMID 29658848, PMID 30280641, PMID 33337539, PMID 35537408, PMID 36184621, PMID 37934000, PMID 38642841, PMID 16757720, PMID 16966690, PMID 19801201, PMID 21502559, PMID 23816960, PMID 24705333, PMID 25436806, PMID 25490004, PMID 25589191, PMID 26028407, PMID 26051236, PMID 26768165, PMID 26823294, PMID 27458945, PMID 28445469, PMID 28472437, PMID 28501139, PMID 28885881, PMID 29151359, PMID 29290251, PMID 29293889

NIH funding

2023 (149), 2016 (69), 2017 (69), 2019 (62), 2018 (61), 2025 (61), 2015 (55), 2014 (52), U10CA031946 (52), U10CA032102 (39), P30CA033572 (32), U10CA180888 (30), P30CA012197 (27), 2009 (26), P30CA043703 (23)